Talag Maria Monica, Alsharedi Mohamed, Bou Zgheib Nadim, Lebowicz Yehuda
St. George's, University of London, London, UK Joan C Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
Joan C Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
BMJ Case Rep. 2016 Sep 13;2016:bcr2016216450. doi: 10.1136/bcr-2016-216450.
Recent advances in novel immunotherapeutic and targeted therapeutic agents have increased treatment options in patients with advanced metastatic melanoma. However, evidence in the literature on whether or not extracutaneous melanoma will acquire an equivalent advantage from these therapies is very scarce. In general, extracutaneous melanomas are rare and aggressive melanomas, which are clinically and biologically unique, with higher incidence of metastatic disease and poor prognosis. In this case report, we present a very rare case of a 54-year-old woman with primary pelvic retroperitoneal melanoma treated with an anti-PD-1 antibody, pembrolizumab. Furthermore, we explore the role of novel immunotherapies in the treatment of advanced melanoma.
新型免疫治疗和靶向治疗药物的最新进展增加了晚期转移性黑色素瘤患者的治疗选择。然而，文献中关于皮肤外黑色素瘤是否能从这些治疗中获得同等益处的证据非常稀少。一般来说，皮肤外黑色素瘤是罕见且侵袭性强的黑色素瘤，在临床和生物学上具有独特性，转移性疾病发生率较高且预后较差。在本病例报告中，我们展示了一例非常罕见的病例，一名54岁女性原发性盆腔腹膜后黑色素瘤接受了抗程序性死亡蛋白1（PD-1）抗体帕博利珠单抗治疗。此外，我们探讨了新型免疫疗法在晚期黑色素瘤治疗中的作用。
